Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 623

1.

Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J; HIV-NAT 017 Study Team.

Antivir Ther. 2009;14(2):241-8.

PMID:
19430099
2.

Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.

Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J; HIV-NAT 017 Study Team.

Pediatr Infect Dis J. 2008 Jul;27(7):623-8. doi: 10.1097/INF.0b013e31816b4539.

PMID:
18520443
3.

Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B; Staccato Thailand Study Group.

Antivir Ther. 2008;13(3):375-80.

PMID:
18572750
4.

Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.

Hoffmann F, Notheis G, Wintergerst U, Eberle J, Gürtler L, Belohradsky BH.

Pediatr Infect Dis J. 2000 Jan;19(1):47-51.

PMID:
10643850
5.

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.

Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B; Frankfurt HIV Cohort.

J Antimicrob Chemother. 2006 Nov;58(5):1024-30. Epub 2006 Sep 6.

PMID:
16956902
6.

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.

Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K; Study Team.

HIV Med. 2007 Nov;8(8):529-35.

7.

Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, Engchanil C, Ruxrungtham K, Burger D; HIV-NAT 017 Study Team.

Pediatr Infect Dis J. 2005 Oct;24(10):874-9.

PMID:
16220084
8.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15821394
9.

The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.

HIV Med. 2005 Mar;6(2):122-8.

10.

A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD; MaxCmin2 Trial Group.

Antivir Ther. 2005;10(6):735-43.

PMID:
16218173
11.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children.

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083
12.

Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.

Cameron DW, Becker S, King MS, da Silva B, Klein C, Tokimoto D, Foit C, Calhoun D, Bernstein B, Hanna GJ.

J Antimicrob Chemother. 2007 May;59(5):957-63. Epub 2007 Mar 9.

PMID:
17350990
13.

Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.

Voigt E, Wasmuth JC, Vogel M, Mauss S, Schmutz G, Kaiser R, Rockstroh JK.

Infection. 2004 Apr;32(2):82-8.

PMID:
15057572
14.

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.

Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A.

AIDS. 2006 May 12;20(8):1131-9.

PMID:
16691064
15.

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70.

PMID:
11981362
16.

Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.

Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.

HIV Med. 2007 May;8(4):226-33.

17.

Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML, Gurbindo MD, Ramos JT, Soler Palacín P, Léon JA, Asensi M, Mellado MJ, Muñoz-Fernández MA.

J Antimicrob Chemother. 2008 Jan;61(1):183-90. Epub 2007 Nov 19.

PMID:
18025025
18.

Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.

Barreiro P, Camino N, de Mendoza C, Valer L, Núñez M, Martín-Carbonero L, González-Lahoz J, Soriano V.

Int J Antimicrob Agents. 2002 Dec;20(6):438-43.

PMID:
12458138
19.

Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.

Gathe JC Jr, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.

Clin Ther. 2006 May;28(5):745-54.

PMID:
16861096
20.

Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study.

Bucher HC, Bichsel M, Taffé P, Furrer H, Telenti A, Hirschel B, Weber R, Bernasconi E, Vernazza P, Minder C, Battegay M; Swiss HIV Cohort Study.

HIV Med. 2002 Oct;3(4):247-53.

Supplemental Content

Support Center